Aktis Oncology (NASDAQ:AKTS) Releases Earnings Results, Misses Estimates By $0.07 EPS

Aktis Oncology (NASDAQ:AKTS) issued its quarterly earnings results on Thursday. The technology company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.07), FiscalAI reports. The firm had revenue of $3.91 million during the quarter, compared to the consensus estimate of $4.02 million.

Aktis Oncology Trading Down 4.5%

AKTS stock traded down $0.77 on Thursday, hitting $16.27. 134,918 shares of the company’s stock traded hands, compared to its average volume of 354,245. The stock has a market cap of $874.46 million and a price-to-earnings ratio of -19.84. Aktis Oncology has a 1-year low of $13.96 and a 1-year high of $34.19. The stock has a fifty day moving average of $18.96 and a 200-day moving average of $20.84.

Wall Street Analyst Weigh In

AKTS has been the subject of several research analyst reports. Oppenheimer began coverage on shares of Aktis Oncology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $40.00 price objective for the company. Weiss Ratings cut shares of Aktis Oncology from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Wall Street Zen cut shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. BMO Capital Markets assumed coverage on shares of Aktis Oncology in a research report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price target on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $35.00 price target on shares of Aktis Oncology in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Aktis Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.62.

About Aktis Oncology

Aktis Oncology, Inc. is a clinical-stage biotechnology company developing targeted radiopharmaceuticals for solid tumors. Its approach uses small protein-based molecules designed to bind cancer-associated targets and deliver radioactive payloads to tumor cells. The company’s pipeline includes investigational programs directed at targets found on solid tumors, including Nectin-4. These candidates are being developed for potential use in patients with advanced cancers; they are not approved for commercial use.